A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2015

At a glance

  • Drugs Eleclazine (Primary) ; Dofetilide
  • Indications Long QT syndrome
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 19 May 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 26 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record .
    • 25 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top